Modeling the long-term efficacy of neratinib in the extended adjuvant setting for women with HER2+/HR+ early stage breast cancer (ESBC). (March 2019) - Doan, Q.; Lalla, D.; Yao, B.; Danese, M.; Barnett, B.; Crown, J.